Read by QxMD icon Read

Lancet HIV

Karl-Günter Technau, Renate Strehlau, Faeezah Patel, Stephanie Shiau, Megan Burke, Martie Conradie, Gillian Sorour, Gayle G Sherman, Ashraf Coovadia, Pamela M Murnane, Elaine J Abrams, Louise Kuhn
BACKGROUND: Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa. METHODS: From September, 2013 (era 1), only high-risk HIV-exposed infants were offered diagnostic HIV PCR tests at birth. From June, 2014 (era 2), all HIV-exposed infants were offered laboratory-based diagnostic PCR tests...
November 8, 2018: Lancet HIV
Ameena Goga
No abstract text is available yet for this article.
November 8, 2018: Lancet HIV
Christian Wejse, Bo L Hønge
No abstract text is available yet for this article.
November 1, 2018: Lancet HIV
Joakim Esbjörnsson, Fredrik Månsson, Anders Kvist, Zacarias J da Silva, Sören Andersson, Eva Maria Fenyö, Per-Erik Isberg, Antonio J Biague, Jacob Lindman, Angelica A Palm, Sarah L Rowland-Jones, Marianne Jansson, Patrik Medstrand, Hans Norrgren
BACKGROUND: HIV type 2 (HIV-2) is considered more benign and has fewer pathogenic consequences than HIV type 1 (HIV-1) for most infected individuals. However, reliable estimates of time to AIDS and mortality among those with HIV-2 infection are absent. We therefore aimed to compare the time to AIDS and mortality, and the CD4 T-cell dynamics between those infected with HIV-1 and HIV-2. METHODS: We did a prospective open cohort study. We included all police officers with regular employment from police stations in both urban and rural areas of Guinea-Bissau since Feb 6, 1990...
November 1, 2018: Lancet HIV
Andrew E Grulich, Rebecca Guy, Janaki Amin, Fengyi Jin, Christine Selvey, Jo Holden, Heather-Marie A Schmidt, Iryna Zablotska, Karen Price, Bill Whittaker, Kerry Chant, Craig Cooper, Scott McGill, Barbara Telfer, Barbara Yeung, Gesalit Levitt, Erin E Ogilvie, Nila J Dharan, Mohamed A Hammoud, Stefanie Vaccher, Lucy Watchirs-Smith, Anna McNulty, David J Smith, Debra M Allen, David Baker, Mark Bloch, Rohan I Bopage, Katherine Brown, Andrew Carr, Christopher J Carmody, Kym L Collins, Robert Finlayson, Rosalind Foster, Eva Y Jackson, David A Lewis, Josephine Lusk, Catherine C O'Connor, Nathan Ryder, Emanuel Vlahakis, Phillip Read, David A Cooper
BACKGROUND: HIV pre-exposure prophylaxis (PrEP) is highly effective in men who have sex with men (MSM) at the individual level, but data on population-level impact are lacking. We examined whether rapid, targeted, and high-coverage roll-out of PrEP in an MSM epidemic would reduce HIV incidence in the cohort prescribed PrEP and state-wide in Australia's most populous state, New South Wales. METHODS: The Expanded PrEP Implementation in Communities-New South Wales (EPIC-NSW) study is an implementation cohort study of daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP...
October 17, 2018: Lancet HIV
Sheena McCormack
No abstract text is available yet for this article.
October 16, 2018: Lancet HIV
Alison P Galvani, Abhishek Pandey, Meagan C Fitzpatrick, Jan Medlock, Glenda E Gray
Although the HIV pandemic remains a global crisis, much progress has been made in implementing programmes to treat and prevent HIV infection. To guide prioritisation of efforts, the metric by which a country can declare its HIV epidemic as controlled has become increasingly relevant. Herein, we evaluate the merits of the four control criteria proposed by UNAIDS: percentage reduction in incidence over time; ratio of incidence to mortality; ratio of incidence to prevalence; and annual incidence. Using a transmission model to generate projections of demography, incidence, and mortality, we highlight potential pitfalls associated with each of the first three criteria...
October 9, 2018: Lancet HIV
Sarah Finocchario-Kessler, Brad Gautney, AnLin Cheng, Catherine Wexler, May Maloba, Niaman Nazir, Samoel Khamadi, Raphael Lwembe, Melinda Brown, Thomas A Odeny, Jacinda K Dariotis, Matthew Sandbulte, Natabhona Mabachi, Kathy Goggin
BACKGROUND: The HIV Infant Tracking System (HITSystem) is a web-based intervention linking providers of early infant diagnosis, laboratory technicians, and mothers and infants to improve outcomes for HIV-exposed infants. We aimed to evaluate the efficacy of the HITSystem on key outcomes of early infant diagnosis. METHODS: We did a cluster-randomised trial at six hospitals in Kenya, which were matched on geographic region, resource level, and volume of patients (high, medium, and low)...
October 8, 2018: Lancet HIV
Richard T Lester
No abstract text is available yet for this article.
October 8, 2018: Lancet HIV
Matthew M Kavanagh, Stefan D Baral, Maureen Milanga, Jeremy Sugarman
Widespread public health surveillance efforts focused on key populations (men who have sex with men, sex workers, people who inject drugs, and others) gather data on population sizes, HIV prevalence, and other information for planning and resource allocation. Biometric identification might improve this data gathering. However, in the context of extensive criminalisation of these populations, the use of biometrics such as fingerprints raises concerns that are insufficiently addressed in current policies. These concerns include infringing privacy, exposing participants to risks of legal action or violence, biasing surveillance results, and undermining trust in the health system...
October 5, 2018: Lancet HIV
Salim S Abdool Karim
No abstract text is available yet for this article.
September 28, 2018: Lancet HIV
Seth C Inzaule, Raph L Hamers, Marc Noguera-Julian, Maria Casadellà, Mariona Parera, Cissy Kityo, Kim Steegen, Denise Naniche, Bonaventura Clotet, Tobias F Rinke de Wit, Roger Paredes
BACKGROUND: Implementation of ultrasensitive HIV drug resistance tests for routine clinical use is hampered by uncertainty about the clinical relevance of drug-resistant minority variants. We assessed different detection thresholds for pretreatment drug resistance to predict an increased risk of virological failure. METHODS: We did a case-control study nested within a prospective multicountry cohort. Our study included patients from 12 clinical sites in Kenya, Nigeria, South Africa, Uganda, and Zambia...
September 28, 2018: Lancet HIV
Philip E Tarr, Alexandra Calmy
No abstract text is available yet for this article.
September 21, 2018: Lancet HIV
Nancy A Hessol, Hannah Whittemore, Eric Vittinghoff, Ling C Hsu, Danning Ma, Susan Scheer, Sandra K Schwarcz
BACKGROUND: Cancer survivors are at increased risk for subsequent primary cancers. People living with HIV are at increased risk for AIDS-defining and non-AIDS-defining cancers, but little is known about their risk of first versus second primary cancers. We identified first and second primary cancers that occurred in above population expected numbers among people diagnosed with HIV in San Francisco, and compared first and second cancer incidence across five time periods that corresponded to important advances in antiretroviral therapy...
September 20, 2018: Lancet HIV
Juan P Jaworski, Pedro Cahn
The viral plasticity and the vast diversity of HIV-1 circulating strains necessitates the identification of new approaches to control this global pandemic. New generation broadly neutralising monoclonal antibodies (bnMAbs) against the HIV-1 viral envelope protein (Env) can prevent virus acquisition, reduce viraemia, enhance immunity, and induce the killing of infected cells in animal models of HIV-1 infection. Most importantly, passively administered bnMAbs are effective at decreasing viraemia and delaying viral rebound in people chronically infected with HIV-1...
September 20, 2018: Lancet HIV
Silvia Franceschi
No abstract text is available yet for this article.
September 20, 2018: Lancet HIV
Chris Beyrer
No abstract text is available yet for this article.
September 13, 2018: Lancet HIV
Weiming Tang, Dan Wu
No abstract text is available yet for this article.
September 10, 2018: Lancet HIV
Anne C Spaulding, Marcia McDonnell Holstad
No abstract text is available yet for this article.
September 6, 2018: Lancet HIV
Kelsey B Loeliger, Frederick L Altice, Maria M Ciarleglio, Katherine M Rich, Divya K Chandra, Colleen Gallagher, Mayur M Desai, Jaimie P Meyer
BACKGROUND: People transitioning from prisons or jails have high mortality, but data are scarce for people with HIV and no studies have integrated data from both criminal justice and community settings. We aimed to assess all-cause mortality in people with HIV released from an integrated system of prisons and jails in Connecticut, USA. METHODS: We linked pharmacy, custodial, death, case management, and HIV surveillance data from Connecticut Departments of Correction and Public Health to create a retrospective cohort of all adults with HIV released from jails and prisons in Connecticut between 2007 and 2014...
September 6, 2018: Lancet HIV
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"